Bristol-Myers Squibb has added Elliott Sigal to its Board of Directors and the Board’s Science and Technology Committee.
Dr Sigal joined Bristol-Myers Squibb in November 1997 as vice president of Applied Genomics. Since then he has served in critical leadership roles within R&D, including drug discovery and development. During his tenure as chief scientific officer, BMS achieved eight new drug approvals and the R&D organisation filled the drug pipeline with an unprecedented number of mid- and late-stage assets, five of which could be approved by 2012.
“We are very excited to have Elliott join our Board,” said James M. Cornelius, Chairman, Bristol-Myers Squibb. “Under his leadership, our R&D organisation has become one of the most productive in the industry. Today’s appointment recognises his great contribution to the company.”
“Elliott’s election to our Board recognizes the importance of R&D to our strategy and our success as a BioPharma company,” added Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb. “Elliott is an important member of my Senior Management Team, a team that joins me in congratulating him on this great honor and his many accomplishments.”